Ethical perspectives in caring for people living with addictions: The European experience

International Review of Psychiatry

Volumn 22, Issue 3, 2010, Pages 274-280

  Uchtenhagen, Ambros A ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; ILLICIT DRUG; METHADONE;

ABSTINENCE; CLINICAL PRACTICE; CLINICAL RESEARCH; DETOXIFICATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; EUROPE; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HUMAN; HUMAN RIGHTS; INFECTION PREVENTION; LEGAL ASPECT; MEDICAL ETHICS; MENTAL HEALTH CARE; OPIATE ADDICTION; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; SOCIETY; SUBSTITUTION THERAPY;

EUROPE; HEALTH PROMOTION; HUMANS; MENTAL HEALTH SERVICES; METHADONE; NARCOTIC ANTAGONISTS; NEEDLE-EXCHANGE PROGRAMS; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS;

EID: 77953345987     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.3109/09540261.2010.482097     Document Type: Review

References (40)

1. Amundsen, E.J. (2006). Measuring effectiveness of needle and syringe exchange programmes for prevention of HIV among injecting drug users. Editorial. Addiction, 101, 911-912.
2. Council of Europe (1950, 4 November). Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine, Rome.
3. Departmental Committee on Morphine and Heroin Addiction (1926). Rolleston Report. London: Her Majesty's Stationery Office.
4. EC (2008). Communication from the Commission to the European Parliament and Council on an EU drugs action plan for 2009-2012 (COM(2008) 567/4). Brussels: Commission of the European Communities.
5. Elster, J., & Shag, O.J. (1999). Getting Hooked. Rationality and Addiction. Cambridge: Cambridge University Press.
6. EMCDDA 2006, National drug strategies. European Monitoring Centre on Drugs and Drug Addiction, Lisbon. Available at: www.emcdda.europa.eu/policy-and- law/national/strategies (accessed March 14, 2010).
7. EMCDDA (2008a). Legal framework of needle and syringe programmes. European legal database on drugs. Available at: http://eldd.emcdda.europa.eu/ html.cfm/index13212EN.html (accessed March 14, 2010).
8. EMCDDA (2008b). Statistical Bulletin 2008. Archives of the European Monitoring Centre on Drugs and Drug Addiction, Lisbon. Available at: www.emcdda.europa.eu/stats08/hsr (accessed March 14, 2010).
9. EMCDDA (2009a). Legal framework and practice of substitution treatment initiation. Statistical Bulletin 2008. Archives of the European Monitoring Centre on Drugs and Drug Addiction, Lisbon. Available at: www.emcdda.europa.eu/ stats08/hsrtab2 (accessed March 14, 2010).
10. EMCDDA (2009b). Treatment as an alternative to prosecution or imprisonment for adults. European Monitoring Centre on Drugs and Drug Addiction, Lisbon. Available at: http://eldd.emcdda.europa.eu/html.cfm/index13223EN.html (accessed March 14, 2010).
11. Emcdda (2009c). Special issue 2009. Drug offences; sentencing and other outcomes. European Monitoring Centre on Drugs and Drug Addiction, Lisbon. Available at: www. emcdda.europa.eu/publications/selected-issues/sentencing- statistics (accessed March 14, 2010).
12. EU (2003). Council Recommendation of 18 June 2003 on the prevention and reduction of health-related harm associated with drug dependence (2003/488/EC). Brussels: European Council.
13. EU (2005). EU drugs action plan 2005-2008 (2005/C 168/01). Official Journal of the European Union (Brussels), 168(7), July 8, 2005.
14. EU (2008). Health Programme 2008-2013. Brussels: European Commission, DG Health and Consumer Protection.
15. Fry, C.L., Khoshnood, K., Power, R., & Sharma, M. (2008). Harm reduction ethics: Acknowledging the values and beliefs behind our actions. International Journal of Drug Policy, 19, 1-3.
16. Gibson, D., Flynn, N.M., & Perales, D. (2001). Effectiveness of syringe exchange programs in reducing HIV risk behaviour and HIV seroconversion among injecting drug users. AIDS, 15, 1329-1541.
17. GMC (2006). Good Medical Practice. Regulating doctors. Ensuring good medical practice. London: General Medical Council.
18. Guggenbühl, L., Uchtenhagen, A., & Fabian, C. (2000). Adequacy in drug abuse treatment and care in Europe (ADAT). Part I: Ethical aspects of the treatment and care of drug addicts. Country reports and ethical guidelines. World Health Organization, Regional Office for Europe. Available at: www.euro.who.int/alcoholdrugs/Publications/20030117-1 (accessed March 14, 2010).
19. Hare, R. (1991). The philosophical basis of psychiatric ethics. In S. Bloch & P. Chodoff (Eds.), Psychiatric Ethics. Oxford: Oxford University Press.
20. Hedrich, D. (2004). European Report on Drug Consumption Rooms. Lisbon: European Monitoring Centre on Drugs and Drug Addiction.
21. Hedrich, D., Pirona, A., & Wiessing, L. (2008). From margin to mainstream: The evolution of harm reduction responses to problem drug use in Europe. Drugs: Education, Prevention and Policy, 15, 503-517.
22. Hunt, N., Ashton, M., Lenton, S., Mitcheson, L., Nelles, B., & Stimson, G. (2003). A review of the evidence base for harm reduction approaches to drug use. London: Forward Thinking on Drugs.
23. Jonas, H. (1984). The imperative of responsibility. In search of ethics for the technological age. Chicago: University of Chicago Press.
24. Kleinig, J. (2006). Thinking ethically about needle and syringe programs. Substance Use & Misuse, 41, 815-825.
25. Klingemann, H., & Sobell, L.C. (2007). Promoting self-change from addictive behaviors. Practical implications for policy, prevention and treatment. New York: Springer.
26. Mill, J.S. (1861, 1963). J.M. Robson (Ed.), Utilitarianism. Collected works. Toronto: Toronto University Press.
27. Moss, A. (1987). AIDS and intravenous drug use: The real heterosexual epidemic. British Medical Journal, 294, 389-390.
28. Polcin, D.L., & Weisner, C. (1999). Factors associated with coercion in entering treatment for alcohol problems. Drug and Alcohol Dependence, 54, 63-68.
29. Stevens, A., Hallam, C., & Trace, M. (2006). Treatment for dependent drug use. A guide for policymakers. London: Beckley Foundation.
30. Stö ver, H., Casselmann, J., & Hennebel, P. (2006). Substitution treatment in European prisons: A study of policies and practices in 18 European countries. International Journal of Prison Health, 2, 3-12.
31. Uchtenhagen, A. (2008). Heroin-assisted treatment. In A. Stevens (Ed.), Crossing frontiers. International Developments in the Treatment of Drug Dependence (pp. 53-82). Brighton: Pavilion.
32. Uchtenhagen, A., & Guggenbühl, L. (2000). Adequacy in drug abuse treatment and care in Europe ADAT. A project of the WHO European Office. Research report from the Addiction Research Institute, Zurich. Available at: www.euro.who.int/ alcoholdrugs/Publications/20030117-1 (accessed March 14, 2010).
33. UN (1948). The Universal Declaration of Human Rights. New York: United Nations.
34. Werdenich, W., Waidner, G., & Trinkl, B. (2004). Quasicompulsory treatment of drug dependent offenders - A description of existing systems. Verhaltenstherapie und Verhaltensmedizin, 25, 71-78.
35. WHO (2004a). Methadone as a medicine for the management of opioid dependence and HIV/Aids prevention. Geneva: World Health Organization.
36. WHO (2004b). Proposal for the inclusion of buprenorphine in the WHO model list of essential medicines. Geneva: World Health Organization.
37. WHO (2005). The Health for All Policy Framework for the WHO European Region. 2005 update. Copenhagen: World Health Organization Regional Office for Europe.
38. WHO (2008). Guidelines for the psychosocially supported pharmacological treatment of opioid dependence. Geneva: World Health Organization.
39. WMA (2000). Helsinki Declaration, 5th revision. World Medical Association, Edinburgh.
40. Wodak, A., & Cooney, A. (2006). Do needle syringe programs reduce HIV infection among injecting drug users: A comprehensive review of the international evidence. Substance Use and Misuse, 41, 777-813.